Literature DB >> 15450383

HSV-2 transmission.

S L Sacks1, P D Griffiths, L Corey, C Cohen, A Cunningham, G M Dusheiko, S Self, S Spruance, L R Stanberry, A Wald, R J Whitley.   

Abstract

A number of important risk factors for the acquisition of HSV-2 have been established including female gender, black or Hispanic ethnic origin, HIV infection, age, and increased number of sexual partners. Transmission is influenced by a number of biological factors such as sexual behavior, use of condoms, duration of relationships, and knowledge of a partner's serologic status. Vertical transmission (transmission of HSV from mother to neonate) is potentially life-threatening; neonatal HSV infection is associated with significant morbidity and mortality. The valaciclovir transmission study provides evidence that an antiviral agent can interrupt the transmission of a viral sexually transmitted disease between serologically discordant sexual partners. This review explores the importance of the cofactors that affect transmission, and makes recommendations on considerations for the prophylactic use of antiviral agents for the prevention of transmission in other patient populations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15450383     DOI: 10.1016/j.antiviral.2004.06.005

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  16 in total

Review 1.  Role of heparan sulfate in sexually transmitted infections.

Authors:  Vaibhav Tiwari; Erika Maus; Ira M Sigar; Kyle H Ramsey; Deepak Shukla
Journal:  Glycobiology       Date:  2012-07-06       Impact factor: 4.313

2.  Addition of a C-terminal cysteine improves the anti-herpes simplex virus activity of a peptide containing the human immunodeficiency virus type 1 TAT protein transduction domain.

Authors:  Hermann Bultmann; Jeremy Teuton; Curtis R Brandt
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

3.  Testing for asymptomatic herpes simplex virus type 2: implications for pretest and post-test counseling.

Authors:  Noreen A Hynes
Journal:  Curr Infect Dis Rep       Date:  2007-03       Impact factor: 3.725

4.  High seroprevalence of herpes simplex virus type 2 infection in French human immunodeficiency virus type 1-infected outpatients.

Authors:  Laurent Andréoletti; Emmanuel Piednoir; Jérôme Legoff; Véronique Brodard; Isabelle Beguinot; Christophe Strady; Christine Rouger; Christophe Piketty; Ali Si-Mohamed; Michel Daniel Kazatchkine; Jean-Elie Malkin; Laurent Bélec
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

5.  The Tail Wagging the Dog (or the Challenges Faced When the Financing of Medicine Gets Ahead of the Science of Medicine).

Authors:  David W Kimberlin
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

6.  Genome-wide engineering of an infectious clone of herpes simplex virus type 1 using synthetic genomics assembly methods.

Authors:  Lauren M Oldfield; Peter Grzesik; Alexander A Voorhies; Nina Alperovich; Derek MacMath; Claudia D Najera; Diya Sabrina Chandra; Sanjana Prasad; Vladimir N Noskov; Michael G Montague; Robert M Friedman; Prashant J Desai; Sanjay Vashee
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-19       Impact factor: 11.205

Review 7.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

8.  Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.

Authors:  Radeekorn Akkarawongsa; Nina E Pocaro; Gary Case; Aaron W Kolb; Curtis R Brandt
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

9.  Seroprevalence and factors associated with herpes simplex virus type 2 among HIV-negative high-risk men who have sex with men from Rio de Janeiro, Brazil: a cross-sectional study.

Authors:  Junia Rodrigues; Beatriz Grinsztejn; Francisco I Bastos; Luciane Velasque; Paula M Luz; Claudia T V de Souza; Ingebourg Georg; Jose H Pilotto; Valdilea G Veloso
Journal:  BMC Infect Dis       Date:  2009-04-01       Impact factor: 3.090

10.  FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection.

Authors:  William A Rose; Chris L McGowin; Richard B Pyles
Journal:  Virol J       Date:  2009-11-10       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.